Biography:
Dr. Gupta did her PhD at Max Planck Institute for Molecular Genetics, Berlin, Germany, studying protein translation, leading to the discovery of 70S-scanning initiation. She then worked at Yale University, focusing on cancer therapeutics, resulting in publications in journals like Cancer Discovery, Cell Reports Medicine, PNAS, Cell Reports etc. Currently, she is Associate Professor and Associate scientist at O'Neal Comprehensive Cancer Center at UAB. Her lab focuses on identifying new molecules and pathways and studying their role in tumor initiation and progression. Her long-term goal is to develop novel, more effective and durable cancer therapies.
ASAH1 drives TNBC progression and is a potential therapeutic target
ATAD2 is a driver and a therapeutic target in ovarian cancer that functions by upregulating CENPE
Co- Targeting of specific epigenetic regulators in combination with CDC7 potently inhibit melanoma growth
DOT1L promotes Ovarian Cancer tumor growth by stimulating pro-tumorigenic metabolic pathways and blocking apoptosis
KLF7 promotes pancreatic cancer growth and metastasis by up - Regulating ISG expression and maintaining Golgi complex integrity